[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:plexiform-neurofibroma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":60,"states":61},"Plexiform Neurofibroma",8,7,[8,16,22,29,35,41,47,53],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06502171","Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas",[12],"Phase 1","RECRUITING","2026-08-26T02:17:40.683658Z","2026-05-05T02:43:27.752091Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06961565","PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas",[12],"2026-08-26T02:19:15.498463Z","2026-05-05T02:43:27.513386Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06188741","Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1",[26],"Phase 2","2026-08-26T02:18:25.327036Z","2026-05-05T02:43:27.426581Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06541847","A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1",[26],"2026-08-26T02:17:04.346841Z","2026-05-05T02:43:27.317314Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT02544022","Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)",[],"2026-08-26T02:17:17.791881Z","2026-05-13T02:55:06.096968Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT06515860","Neurofibromatosis Type 1 Tumor Early Detection Study",[],"2026-08-03T02:47:17.144574Z","2026-05-13T02:55:06.496843Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT06222203","Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)",[],"2026-08-26T02:18:21.216897Z","2026-05-13T02:55:06.427261Z",{"nct_id":54,"title":55,"phases":56,"status":57,"updated_at":58,"content_modified":59},"NCT05238909","Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1",[],"ENROLLING_BY_INVITATION","2026-08-26T02:19:10.436356Z","2026-06-16T05:54:08.026991Z",[],[62,66,69,72,75,78,81,85],{"state":63,"count":64,"slug":65},"Alabama",4,"alabama",{"state":67,"count":64,"slug":68},"District of Columbia","district-of-columbia",{"state":70,"count":64,"slug":71},"Illinois","illinois",{"state":73,"count":64,"slug":74},"Maryland","maryland",{"state":76,"count":64,"slug":77},"Ohio","ohio",{"state":79,"count":64,"slug":80},"Pennsylvania","pennsylvania",{"state":82,"count":83,"slug":84},"Massachusetts",3,"massachusetts",{"state":86,"count":83,"slug":87},"Texas","texas"]